









A reduced dose of darunavir/ritonavir is effective  
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ABSTRACT
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ri-
tonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIV-
positive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the 
dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced 
HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) suc-
cessfully controlled viral replication 
Keywords: HIV infections; pharmacokinetics antiretroviral therapy, highly active.
and lopinavir/ritonavir. However, the pa-
tient developed severe hypertriglyceridemia 
(> 1,000 mg/dL) and, despite introduction of 
fenofibrate and omega 3 fatty acids, normaliza-
tion of plasma triglycerides was not obtained. 
In July 2008 (CD4 cells 772/μL, HIV-RNA 
< 50 copies/mL) the patient was switched 
to DRV/r 600/100 mg once daily trying to 
reduce triglyceride plasma levels (still over 
500 mg/dL). A genotypic resistance test 
(TRUGENE HIV-1, Bayer Healthcare) per-
formed on PBMC showed resistance muta-
tions for NRTIs, NNRTIs (41L, 44D, 74V, 
101Q, 103H, 108I, 118I, 181C, 184V, 190A, 
210W, 215Y, 219R) and PIs (10I, 20M, 36I, 
46I, 58E, 63T, 84V, 90M) with one DRV resist-
ance mutation according to the International 
AIDS Society USA panel resistance testing.7
One month after the switch CD4 cells 
were 768/μL and viral load was undetectable. 
In January 2009 CD4 lymphocytes rose to 
869/μL, HIV-RNA continued to be unde-
tectable, and triglyceride level dropped 
to 334 mg/dL on fenofibrate only. In 
March 2009 trough concentration of 
DRV (determined through a validated 
high performance liquid chromatogra-
phy method)8 was 3442 ng/mL. In June 
2009 CD4 cells were 834/μL, HIV-RNA 
< 50 copies/mL and plasma triglycerides 
224 mg/dL. Fifteen months later (Septem-
ber 2010) CD4 cell count was 940/μL and 
HIV-RNA < 50 copies/mL.
INTRODUCTION
Darunavir (DRV) is a licensed protease inhibi-
tor with binding characteristics that predict less 
frequent development of resistance and higher 
activity against resistant viruses than ear-
lier protease inhibitors.1 For treatment-naïve 
HIV-infected patients, the ARTEMIS trial es-
tablished the efficacy of the 800/100 mg once-
daily dose of darunavir/ritonavir (DRV/r).2 In 
addition, this dose is effective also in treatment-
experienced patients.3-5 The once daily dosing is 
supported by the relatively long terminal elimi-
nation plasma half-life of DRV (15 hours).6
We report our results in seven antiretrovi-
ral therapy (ART)-experienced HIV-infected 
patients, in whom a reduced dose of DRV/r 




A 45-year-old man, HIV-infected from 1992 
(CDC C3), who started ART in 1993. After 
initial zidovudine monotherapy, combi-
nation regimens were used (zidovudine-
didanosine-nelfinavir for four years, then 
zidovudine-didanosine-efavirenz for three 
years) but full virological suppression (HIV-
RNA < 50 copies/mL) was reached only in 
February 2003, when his antiretroviral regi-
men was changed to stavudine, lamivudine 
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Patient 2
A 42-year-old man, HIV stage (CDC B3), treated with zi-
dovudine from 1993. He changed many times his antiret-
roviral regimens (due to only partial adherence, side effects 
and/or virological failure) until February 2006, when he de-
cided to stop therapy. In January 2007 he came back to our 
attention because of weight loss and weakness. His CD4 cell 
count was 23/μL and HIV-RNA level was 41,312 copies/mL. 
We restarted therapy using tenofovir/emtricitabine. In July 
2007 unboosted fosamprenavir (1,400 mg twice daily) was 
added, but the patient was again non compliant. In October 
2007 CD4 cells rose to 56/μL and HIV-RNA went down to 
13,831 copies/mL. In June 2008 CD4 cells were 32/μL and 
HIV-RNA was 33,250 copies/mL.
Following a negative HLA-B*5701 genetic screening and 
a genotypic resistance test that showed resistance mutations 
for NRTIs, NNRTIs (67N, 184V, 190A, 208Y, 215Y) and 
PIs (10I, 13V, 15V, 31I, 46I, 47V, 63P, 77I) with one DRV 
resistance mutation,7 in September 2008 he was started on 
abacavir/lamivudine and DRV/r 600/100 mg once daily and 
3 months later the viral load became undetectable and CD4 
cells were 76/μL. In March 2009 trough concentration of 
DRV was 2,143 ng/mL, and in May 2009 viral load was still 
undetectable and CD4 cells were 209/μL. In October 2009 his 
CD4 cell count was 231/μL and HIV-RNA < 50 copies/mL. 
In October 2010 the CD4 cell count rose to 468/μL with un-
detectable HIV-RNA.
Patient 3
A 47-year-old woman with HIV-1 infection (CDC B2) 
known from 1987, who started antiretroviral therapy in 
1995 with zidovudine. Her antiretroviral treatment history 
was characterized by multiple virological failures (related to 
a partial adherence to ART) and different antiretroviral drug 
combinations used. In September 2008 a genotypic resist-
ance test was performed while she was on zidovudine/lami-
vudine plus tenovofir, with a CD4 cell count of 271/μL and 
a viral load of 15,226 copies/mL. The test showed resistance 
mutations for NRTIs (41L, 184V, 210W, 214F, 215Y) and PIs 
(10I, 63P, 71T, 73T, 84wt/V, 90M, 93L). To favor adherence 
she was switched to tenofovir/emtricitabine plus DRV/r 
600/100 mg once daily. After 24 months (October 2010) 
the patient was still aviremic (HIV-RNA < 50 copies/mL) 
and CD4 cells were 428/μL. Trough concentration of DRV, 
evaluated in February 2010, was 4,518 ng/mL.
Patient 4
A 46-year-old woman with HIV-1 infection (CDC A2), 
started ART (stavudine, lamivudine and indinavir) in 1997. 
After three years she was switched to stavudine, didano-
sine and efavirenz for virological failure. She continued this 
regimen for eight years without ever obtaining a complete 
suppression of plasma viral load, which was anyway below 
1,000 copies/mL and did not allow for antiretroviral geno-
typing resistance tests to be performed. In May 2008, the 
antiretroviral regimen was modified for lipodistrophy and 
tenofovir/emtricitabine plus fosamprenavir/ritonavir were 
started. One month later the viral load was undetectable and 
CD4 cells were 433/μL. In September 2008, the viral load 
was 123 copies/mL. In February 2009, the viral load was 
512 copies/mL. In June 2009,(HIV-RNA 586 copies/mL) 
a genotypic resistance test gave the following results: re-
sistance mutations for NRTIs and NNRTIs 67N, 69D, 74V, 
100I,103 N, 118I, 184V, 210W, 215Y, 221Y, and resistance 
mutations for PIs 10I, 13V, 41K, 46L, 64V, 82F, 93L. In July 
2009, a new antiretroviral regimen was started and, to fa-
vor adherence, raltegravir (800 mg once daily) and DRV/r 
(600 mg plus 100 mg of ritonavir once daily) were intro-
duced. After one month HIV-RNA was < 50 copies/mL 
and the CD4 cell count rose to 557/μL. In November 2010 
(16 months after beginning this regimen, the viral load was still 
undetectable with a CD4 cell count of 651/μL); TDM for DRV 
gave a trough concentration of 844 ng/mL in February 2010.
Patient 5
A 44-year-old woman, HIV-1 infection (CDC A2), started 
her first antiretroviral regimen in 1996. After various regi-
mens the last genotypic resistance test gave the following 
results, while she was on emtricitabine/tenofovir, atazana-
vir/ritonavir and HIV-RNA level was 8,450 copies/mL: re-
sistance mutations for NRTIs and NNRTIs 41L, 74V, 184V, 
210W, 215Y, and resistance mutations for PIs 10F, 35G, 43T, 
50L, 71V, 73S, 74S, 90M.
In March 2010, the patient started emtricitabine/tenfo-
vir plus DRV/r (600/100 mg once daily), and in September 
2010 her viral load was < 50 copies/mL with a CD4 cell 
count of 882/μL.
Patient 6
A 41-year-old man, HIV-1 infection (CDC C3), started on 
ART in 2003 (zidovudine/lamivudine and lopinavir/ritona-
vir). After two months the regimen was switched to dida-
nosine, zidovudine and nevirapine for gastrointestinal side 
effects related to lopinavir/ritonavir. In August 2004, this 
regimen failed (HIV-RNA 17,546 copies/mL). The patient 
defaulted and returned to our attention after 9 months, 
with a CD4 cell count of 296/μL and HIV-RNA 44,549 cop-
ies/mL. We decided to start a new antiretroviral regimen 
consisting of didanosine, lamivudine and atazanavir/rito-
navir. In December 2005, the CD4 cell count was 509/μL 
with undetectable HIV-RNA. In March 2009, HIV-RNA 
rose to 1,158 copies/mL with a CD4 cell count of 546/μL. 
A genotypic resistance test showed the following resistance 
mutations: 215N and 33F, 34Q, 36V, 50L, 63P, 71V, 77I, 82A, 
93L. The patient defaulted again and 10 months later came 
back to our attention with a relapse of PCP. His CD4 cell 
Lanzafame, Bonora, Lattuada et al.
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count was 83/μL and HIV-RNA was 111,426 copies/mL. 
Emtricitabine/tenofovir and lopinavir/ritonavir were start-
ed. At the end of February 2010, with persistent gastrointes-
tinal side effects, the patient was switched from lopinavir/r 
to darunavir/r (600/100 mg once daily). In October 2010, 
the CD4 cell count had raised to 216/μL and HIV-RNA was 
undetectable.
Patient 7
A 44-year-old woman, HIV-1 infection (CDC C3), multid-
rug experienced. After the last failure in 2004, a genotypic 
resistance test was performed (resistance mutations 67N, 
70R, 100I, 103N, 215Y, 219E and 10I, 63P, 82A). She was put 
on lamivudine, abacavir and lopinavir/ritonavir. In Septem-
ber 2010, she refused to continue her antiretroviral regimen 
for long-term side effects (alopecia and lypodistrophy). We 
began DRV/r (600/100 mg once daily) monotherapy and 
four months later the patient was aviremic.
DISCUSSION
Darunavir binds with very high affinity to HIV-1 protease 
and fits closely within the substrate envelope, two factors 
associated with its potency and high genetic barrier.8 DRV 
plus a low boosting dose of ritonavir is approved for use in 
treatment-experienced adults with HIV-1 infection, and for 
use in treatment-naïve adults at the dosage of 800/100 mg 
once-daily.9 Some evidence indicates that this dose can be 
used also for a few treatment-experienced patients.3-5 Our 
results show that a lower DRV/r dose (600/100 mg once dai-
ly) can be used safely and successfully in highly experienced 
patients.
Indeed pharmacokinetic analysis available for four pa-
tients, trough concentration values above the protein-bind-
ing-corrected DRV IC50 for protease inhibitor-resistant vi-
ruses (550 ng/mL).10 Genotypic resistance tests showed that 
this regimen was effective even in the presence of one major 
DRV-associated mutation. 
Recently it has been showed that among different resist-
ance interpretation algorithms and derived gIQs, gIQ WS 
was the most accurate predictive model for achieving a suc-
cessful virological response.11 In all of our four patients with 
pharmacokinetic analysis gIQ WS was always ≥ 600 and pre-
dictable of 48 weeks virological response.
On the basis of our experience, we think that a 
600/100 mg once daily DRV/r dose could be tested in 
large, well powered efficacy trials, in comparison with the 
recognized standard of care.
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